As haemophilia is a life-long condition, continuing supervision by a group of medical personnel is required. In many countries this is provided by comprehensive care haemophilia centres where staff of all specialities concerned with treatment- haematologists, paediatricians, nurses, physiotherapists, orthopaedic surgeons - have specialized knowledge. This new book is a definitive resource on the current aspects and issues around haemophilia. Complications of haemophilia care are well covered in chapters on inhibitors, and musculoskeletal problems, as are all the latest developments in the field of haemophilia.

Textbook of Hemophilia, 3rd edition Edited by Christine A. Lee, MA, MD, DSc, FRCP, FRCPath, FRCOG Emeritus Professor of Haemophilia, University of London, London, UK Erik E. Berntorp, MD, PhD Professor of Coagulation Medicine, Lund University Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden W. Keith Hoots, MD Director, Division of Blood Diseases and Resources, National Heart, Lung and Blood Institute National Institutes of Health, Bethesda, MD; Professor of Pediatrics and Internal Medicine, University of Texas Medical School at Houston, Houston, TX, USA Without doubt, Textbook of Hemophilia, 3rd edition is the definitive reference source on all aspects of haemophilia including diagnosis, management and treatment. Edited by three, world-renowned experts on haemophilia, this completely revised resource features chapters written by over 60 international contributors with international expertise in caring for haemophilia patients. Textbook of Hemophilia, 3rd edition Features eight new chapters, covering individualised dosing, vCJD and haemophilia, new drugs in the pipeline, and surgery in inhibitor patients Presents new developments, such as gene therapy Highlights controversial issues and provides advice for everyday clinical questions Represents essential reading for all healthcare professionals involved in the care of those with haemophilia Titles of related interest Hemophilia and Hemostasis: A Case-Based Approach to Management, 2nd Edition Ma, ISBN: 9780470659762 Current and Future Issues in Hemophilia Care Rodriguez-Merchan, ISBN: 9780470670576 www.wiley.com/go/hematology

This book describes in detail the clinical presentation, diagnosis, and management of a wide range of congenital bleeding disorders. It will assist readers in overcoming the significant challenges involved in clinical and laboratory diagnosis and in providing effective clinical care that makes optimal use of new products, including recombinant factor concentrate. The coverage ranges from hemophilia A and B and von Willebrand disease to rare bleeding disorders such as congenital factor V, factor X, factor XI, and factor XIII deficiency and inherited platelet function disorders. The exceptional attention to rarer conditions is of particular importance given the considerable risk of overlooking them during diagnosis, with potential consequences for disease-related morbidity and mortality. The authors are acknowledged specialists in the field from across the world who have particular expertise in the disorder that they discuss. The book will be of value to hematologists, oncologists, pediatricians, laboratory specialists and technicians, general physicians, and trainees.

Over the past forty years the availability of coagulation factor replacement therapy has greatly contributed to the improved care of people with hemophilia. Following the blood-borne viral infections in the late 1970s and early 1980, caused by coagulation factor concentrates manufactured using non-virally inactivated pooled plasma, the need for safer treatment became crucial to the hemophilia community. The introduction of virus inactivated plasma-derived coagulation factors and then of recombinant products has revolutionized the care of these people. These therapeutic weapons have improved their quality of life and that of their families and permitted home treatment, i.e., factor replacement therapy at regular intervals in order to prevent both bleeding and the resultant joint damage (i.e. primary prophylaxis). Accordingly, a near normal lifestyle and life-expectancy have been achieved. The main current problem in hemophilia is the onset of alloantibodies inactivating the infused coagulation factor, even though immune tolerance regimens based on long-term daily injections of large dosages of coagulation factors are able to eradicate inhibitors in approximately two-thirds of affected patients. In addition availability of products that bypass the intrinsic coagulation defects have dramatically improved the management of this complication. The major challenges of current treatment regimens, such the short half life of hemophilia therapeutics with need for frequent intravenous injections, encourage the current efforts to produce coagulation factors with more prolonged bioavailability. Finally, intensive research is devoted to gene transfer therapy, the only way to ultimately obtain cure in hemophilia.